EXETER, England, November 16 /PRNewswire/ -- Mobious Genomics, in association with Mobious Biosystems, is pleased toannounce the availability of its ExtendaSeq(TM) chemistry plug-in for nextgeneration Sequencing-by-Synthesis chemistry platforms. This chemistry,invented by Mobious's founder Daniel Densham will greatly increase theutility and value of existing next-generation sequencing chemistries via readlength extension.
The ExtendaSeq(TM) chemistry plug-in allows currently available nextgeneration SBS chemistry platform read lengths to be extended by a factor often times or greater.
Daniel Densham, managing director of Mobious Biosystems, owner of theExtendaseq(TM) and partner company Mobious Genomics commented:-
"Next Generation sequencing platforms and their associated chemistriesare rapidly gaining traction in the commercial life science market. This ismainly happening as high levels of sample parallelisation deliver drasticcost reductions. However, as these technologies are increasingly applied tothe high-value field of sequence discovery (De Novo) sequencing, rather thanto less demanding re-sequencing applications, read length is rapidly becomingone of, if not the most important performance characteristics of nextgeneration sequencing methods. Mobious is therefore understandably excitedabout the forthcoming commercial application of our ExtendaSeq(TM) chemistryplug-in".
The ExtendaSeq(TM) chemistry plug-in is suitable for a number of thirdparty chemistry platforms, including as those sold by 454 Corporation, Solexaand Helicos. Further, a new version of the plug-in currently underdevelopment, the ExtendaSeq-ligate(TM), is designed to significantly increasethe read lengths of ligation based chemistries, such as those being developedby Applied Biosystems/Agencourt Personal Genomics.
Notes to Editors
Mobious Genomics is pioneering the development of fundamentally newtechnologies in the fields of genetic analysis and proteomics.
By unifying biological molecular systems and artificial nanostructures,Mobious has created a range of next generation diagnostic and research tools,able to materially outperform current platforms at a fraction of the cost.The group's research has resulted in new technologies and IP in such fieldsas single molecule sequencing, sequencing by synthesis, ultra highlymultiplexed real-time PCR and affinity acceleration for biochips.
Mobious believes that its technology has the potential to help transformthe acquisition and use of genetic knowledge in the global healthcare anddetection industries.
For more information please contact: Daniel Densham, Mobious Genomics +44(0)8700-112-500 licenseportal@mobious.com www.mobious.com
Mobious Genomics
For more information please contact: Daniel Densham, Mobious Genomics +44(0)8700-112-500, licenseportal@mobious.com, www.mobious.com
